Literature DB >> 16291766

Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast.

Sócrates Herrera1, Andrés Gómez, Omaira Vera, Juana Vergara, Augusto Valderrama-Aguirre, Amanda Maestre, Fabián Méndez, Ruobing Wang, Chetan E Chitnis, Syed S Yazdani, Myriam Arévalo-Herrera.   

Abstract

The Duffy antigen (Fy) is necessary for Plasmodium vivax invasion of human erythrocytes. Some populations have a highly prevalent Fy-negative phenotype; such persons are naturally protected from P. vivax blood infection but are expected to completely support the P. vivax pre-erythrocytic cycle, representing a valuable model for studying the immune response during these parasitic stages. We typed 214 individuals, mostly Afro-Colombians, from a P. vivax-endemic area for Fy expression and determined the antibody response to P. vivax pre-erythrocytic (sporozoites and CS) and blood-stage antigens (blood forms, P. vivax merozoite surface protein 1, and P. vivax Duffy binding protein [PvDBP]). Antibody titers to P. vivax circumsporozoite protein, P11, and N-terminal peptides and the number of responders were similar in Fy-negative and Fy-positive individuals. The number of responders to sporozoites, blood forms, and PvDBP were different between these groups. Thus, Fy-negative individuals from malaria-endemic areas can be used to study the immune response to the P. vivax liver phase without interference of the erythrocytic cycle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291766     DOI: 10.4269/ajtmh.2005.73.44

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  23 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Plasmodium vivax pre-erythrocytic-stage antigen discovery: exploiting naturally acquired humoral responses.

Authors:  Douglas M Molina; Olivia C Finney; Myriam Arevalo-Herrera; Socrates Herrera; Philip L Felgner; Malcolm J Gardner; Xiaowu Liang; Ruobing Wang
Journal:  Am J Trop Med Hyg       Date:  2012-07-23       Impact factor: 2.345

3.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Authors:  Sócrates Herrera; Olga Lucía Fernández; Omaira Vera; William Cárdenas; Oscar Ramírez; Ricardo Palacios; Mario Chen-Mok; Giampietro Corradin; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.

Authors:  Luciane M Storti-Melo; Wanessa C Souza-Neiras; Gustavo C Cassiano; Leonardo C Taveira; Antônio J Cordeiro; Vanja S C A Couto; Marinete M Póvoa; Maristela G Cunha; Diana M Echeverry; Andréa R B Rossit; Myriam Arévalo-Herrera; Sócrates Herrera; Ricardo L D Machado
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Malaria-related anemia in patients from unstable transmission areas in Colombia.

Authors:  Mary Lopez-Perez; Álvaro Álvarez; Juan B Gutierrez; Alberto Moreno; Sócrates Herrera; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2014-12-15       Impact factor: 2.345

Review 6.  Red blood cell polymorphism and susceptibility to Plasmodium vivax.

Authors:  Peter A Zimmerman; Marcelo U Ferreira; Rosalind E Howes; Odile Mercereau-Puijalon
Journal:  Adv Parasitol       Date:  2013       Impact factor: 3.870

7.  Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Authors:  Amanda Maestre; Carlos Muskus; Victoria Duque; Olga Agudelo; Pu Liu; Akihide Takagi; Francis B Ntumngia; John H Adams; Kim Lee Sim; Stephen L Hoffman; Giampietro Corradin; Ivan D Velez; Ruobing Wang
Journal:  PLoS One       Date:  2010-07-15       Impact factor: 3.240

8.  Investigating zoonotic infection barriers to ape Plasmodium parasites using faecal DNA analysis.

Authors:  Dorothy E Loy; Meagan A Rubel; Alexa N Avitto; Weimin Liu; Yingying Li; Gerald H Learn; Alessia Ranciaro; Eric Mbunwe; Charles Fokunang; Alfred K Njamnshi; Paul M Sharp; Sarah A Tishkoff; Beatrice H Hahn
Journal:  Int J Parasitol       Date:  2018-02-21       Impact factor: 3.981

9.  Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.

Authors:  Sai Lata De; Samuel May; Keshav Shah; Michelle Slawinski; Siriruk Changrob; Shulin Xu; Samantha J Barnes; Patchanee Chootong; Francis B Ntumngia; John H Adams
Journal:  Vaccine       Date:  2021-04-08       Impact factor: 3.641

10.  Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover.

Authors:  Wathsala Wijayalath; Sandra Cheesman; Kazuyuki Tanabe; Shiroma Handunnetti; Richard Carter; Sisira Pathirana
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.